TP53BP1 and neoplasm: Interestingly, tumor cells were more sensitive to POLQ inhibitors when the expression of 53BP1 in BRCA-deficient cells was reduced, suggesting that ART558 may resensitize patients with acquired resistance to PARPi by inhibiting DNA end excision protection (Zatreanu et al., 2021).